Viveve Medical (VIVE) 10-K 19 Mar 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 13, 2020	Jun. 28, 2019
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	0000879682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		10,027,883
Entity Public Float			$ 17,634,014
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 13,308,000	$ 29,523,000
Accounts receivable, net of allowance for doubtful accounts of $407 and $284 as of December 31, 2019 and 2018, respectively	1,573,000	5,704,000
Inventory	4,861,000	4,119,000
Prepaid expenses and other current assets	2,447,000	2,558,000
Total current assets	22,189,000	41,904,000
Property and equipment, net	3,046,000	2,916,000
Investment in limited liability company	1,216,000	1,843,000
Other assets	526,000	171,000
Total assets	26,977,000	46,834,000
Current liabilities:
Accounts payable	1,608,000	3,994,000
Accrued liabilities	4,698,000	6,766,000
Total current liabilities	6,306,000	10,760,000
Note payable, noncurrent portion	3,983,000	30,528,000
Other noncurrent liabilities	167,000	634,000
Total liabilities	10,456,000	41,922,000
Commitments and contingences (Note 9)
Stockholders’ equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized as of December 31, 2019 and 2018; 7,075,684 and 463,630 shares issued and outstanding as of December 31, 2019 and 2018, respectively	1,000
Additional paid-in capital	214,431,000	160,297,000
Accumulated deficit	(197,911,000)	(155,385,000)
Total stockholders’ equity	16,521,000	4,912,000
Total liabilities and stockholders’ equity	26,977,000	46,834,000
Series A Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock
Series B Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 407	$ 284
Convertible preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	7,075,684	463,630
Common stock, shares outstanding (in shares)	7,075,684	463,630
Series A Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	1,852,173	0
Convertible preferred stock, shares outstanding (in shares)	1,852,173	0
Series B Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	31,678	0
Convertible preferred stock, shares outstanding (in shares)	31,678	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue	$ 6,567,000	$ 18,517,000
Cost of revenue	5,551,000	11,197,000
Gross profit (loss)	1,016,000	7,320,000
Operating expenses:
Research and development	8,590,000	13,616,000
Selling, general and administrative	22,363,000	38,669,000
Restructuring costs	742,000
Total operating expenses	31,695,000	52,285,000
Loss from operations	(30,679,000)	(44,965,000)
Loss on debt restructuring	(6,705,000)
Interest expense, net	(4,354,000)	(4,372,000)
Other income (expense), net	(161,000)	13,000
Net loss from consolidated companies	(41,899,000)	(49,324,000)
Loss from minority interest in limited liability company	(627,000)	(657,000)
Comprehensive and net loss	(42,526,000)	(49,981,000)
Series B convertible preferred stock dividends	(380,000)
Net loss attributable to common stockholders	$ (42,906,000)	$ (49,981,000)
Net loss per share of common stock:
Basic and diluted (in dollars per share)	$ (34.39)	$ (160.92)
Weighted average shares used in computing net loss per common share:
Weighted average shares (in shares)	1,247,768	310,589

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	December 2018 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	December 2018 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	December 2018 Offering [Member]Common Stock [Member]	December 2018 Offering [Member]Additional Paid-in Capital [Member]	December 2018 Offering [Member]Retained Earnings [Member]	December 2018 Offering [Member]	February 2018 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	February 2018 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	February 2018 Offering [Member]Common Stock [Member]	February 2018 Offering [Member]Additional Paid-in Capital [Member]	February 2018 Offering [Member]Retained Earnings [Member]	February 2018 Offering [Member]	November 2017 ATM Facility [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	November 2017 ATM Facility [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	November 2017 ATM Facility [Member]Common Stock [Member]	November 2017 ATM Facility [Member]Additional Paid-in Capital [Member]	November 2017 ATM Facility [Member]Retained Earnings [Member]	November 2017 ATM Facility [Member]	August 2019 ATM Facility [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	August 2019 ATM Facility [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	August 2019 ATM Facility [Member]Common Stock [Member]	August 2019 ATM Facility [Member]Additional Paid-in Capital [Member]	August 2019 ATM Facility [Member]Retained Earnings [Member]	August 2019 ATM Facility [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	November 2019 Offering [Member]Common Stock [Member]	November 2019 Offering [Member]Additional Paid-in Capital [Member]	November 2019 Offering [Member]Retained Earnings [Member]	November 2019 Offering [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Preferred Stock [Member]	Total
Balances (in shares) at Dec. 31, 2017																																	195,033
Balances at Dec. 31, 2017																																		$ 102,981	$ (105,581)		$ (2,600)
Stock offering, net of issuance costs (in shares)			147,285						115,000						2,771			2,771
Stock offering, net of issuance costs				$ 20,384		$ 20,384				$ 32,214		$ 32,214				$ 1,193		$ 1,193
Stock-based compensation expense																																		2,699			2,699
Issuance of restricted stock awards to directors, employees and consultants (in shares)																																	1,285
Issuance of restricted stock awards to directors, employees and consultants																																		336			336
Issuance of restricted common shares (in shares)																																	1,000
Issuance of restricted common shares																																		257			257
Issuance of common shares from employee stock purchase plan (in shares)																																	1,256
Issuance of common shares from employee stock purchase plan																																		233			233
Cumulative effect adjustment from adoption of new accounting standard – ASC 606																																			177		177
Net loss																																			(49,981)		(49,981)
Balances (in shares) at Dec. 31, 2018																																	463,630
Balances at Dec. 31, 2018																																		160,297	(155,385)		4,912
Stock offering, net of issuance costs (in shares)																		0			1,004,171			1,004,171	5,473,410		1,945,943
Stock offering, net of issuance costs																						$ 6,322		$ 6,322			$ 1	$ 9,951		$ 9,952
Stock-based compensation expense																																		2,251			2,251
Issuance of restricted stock awards to directors, employees and consultants (in shares)																																	1,169
Issuance of restricted stock awards to directors, employees and consultants																																		74			74
Issuance of restricted common shares (in shares)																																	38,689
Issuance of restricted common shares																																		75			75
Issuance of common shares from employee stock purchase plan (in shares)																																	1,531
Issuance of common shares from employee stock purchase plan																																		56			56
Net loss																																			(42,526)		(42,526)
Conversion of Series A convertible preferred stock into common stock (in shares)																															(3,621,237)
Conversion of Series A convertible preferred stock into common stock
Conversion of Series A convertible preferred stock into common stock (in shares)																																	3,621,237
Issuance of Series B convertible preferred stock and common stock warrants in connection with debt conversion, net of issuance costs (in shares)																																31,300
Issuance of Series B convertible preferred stock and common stock warrants in connection with debt conversion, net of issuance costs																																		35,413			35,413
Series B convertible preferred stock dividends (in shares)																																378,000				378
Series B convertible preferred stock dividends																																		(2)			(2)
Reverse stock split - cancellation and payout of fractional shares (in shares)																																	(686)
Reverse stock split - cancellation and payout of fractional shares																																		(6)			(6)
Balances (in shares) at Dec. 31, 2019																															1,852,173	31,678	7,075,684
Balances at Dec. 31, 2019																																	$ 1	$ 214,431	$ (197,911)		$ 16,521

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (42,526,000)	$ (49,981,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts and write off of accounts receivable	1,028,000	179,000
Depreciation and amortization	1,177,000	786,000
Stock-based compensation	2,400,000	3,035,000
Fair value of common shares issued		256,000
Non-cash interest expense	1,577,000	1,580,000
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities	5,000
Loss on debt restructuring	6,705,000
Loss from minority interest in limited liability company	627,000	657,000
Loss on disposal of property and equipment	108,000
Changes in assets and liabilities:
Accounts receivable	3,103,000	330,000
Inventory	(1,070,000)	(1,986,000)
Prepaid expenses and other current assets	111,000	183,000
Other noncurrent assets	40,000	31,000
Accounts payable	(2,386,000)	(805,000)
Accrued and other liabilities	(1,536,000)	2,143,000
Other noncurrent liabilities	(599,000)	502,000
Net cash used in operating activities	(31,236,000)	(43,090,000)
Cash flows from investing activities:
Purchase of property and equipment	(1,087,000)	(2,142,000)
Net cash used in investing activities	(1,087,000)	(2,142,000)
Cash flows from financing activities:
Proceeds from equity financings, net of issuance costs	16,274,000	53,792,000
Proceeds from issuance of common shares from employee stock purchase plan	56,000	233,000
Transaction costs in connection with note payable	(216,000)
Reverse stock split - cancellation and payout of fractional shares	(6,000)
Net cash provided by financing activities	16,108,000	54,025,000
Net increase (decrease) in cash and cash equivalents	(16,215,000)	8,793,000
Cash and cash equivalents - beginning of period	29,523,000	20,730,000
Cash and cash equivalents - end of period	13,308,000	29,523,000
Supplemental disclosure:
Cash paid for interest	2,508,000	2,673,000
Cash paid for income taxes		2,000
Supplemental disclosure of cash flow information as of end of period:
Issuance of Series B convertible preferred stock and common stock warrants in connection with debt conversion	35,529,000
Issuance of note payable in settlement of accrued interest	1,226,000	1,256,000
Issuance of Series B convertible preferred stock in settlement of dividends	378,000
Net transfer of equipment between inventory and property and equipment	207,000	257,000
Operating cash outflows from operating leases	295,000
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842)	$ 629,000

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency 2019 In November 2019, “November 2019 $11,500,000, $9,952,000. The offering comprised of: ( 1 $1.55 one one $1.55 first one $1.55 fifth 2 $1.55 one one one $1.55 first one $1.55 fifth The securities comprising the units were immediately separable and were issued separately. A total of 1,945,943 5,473,410 7,419,353 7,419,353 In November December 2019, 600,000 3,021,237 December 31, 2019, 1,852,173 In connection with the closing of the November 2019 $28,981,000 $31,300,000, 31,300 9,893,776 7 5 120% $1.53 $1.836 one ATM Equity Offerings The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, August 16, 2019, may $6,760,000 “August 2019 $6,760,000 August 2019 September 2019. December 31, 2019, 1,004,171 August 2019 $6,322,000. December 31, 2019, no August 2019 The Company had previously established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, November 8, 2017, $25,000,000 “November 2017 August 16, 2019, November 2017 November 7, 2017. no November 2017 December 31, 2019, zero November 2017 December 31, 2018, 2,771 November 2017 $1,193,000. November 2017 August 2019, 3,364 $1,318,000. 2018 In December 2018, “December 2018 147,285 $22,093,000. $20,384,000. In February 2018, “February 2018 115,000 $34,500,000. $32,214,000. Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of December 31, 2019, $197,911,000, $13,308,000 $15,883,000. $31,236,000 December 31, 2019. March 31, 2021. not one To fund further operations, the Company will need to raise additional capital. The Company may no not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard-Leases The Company adopted FASB’s Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2019, one 16% December 31, 2018, one 21% There were no 10% December 31, 2019 2018. As of December 31, 2019, two 49% December 31, 2018, three 54% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $407,000 $284,000 December 31, 2019 2018, During the year ended December 31, 2019, $1,028,000 no December 31, 2018. Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2019 $4,051,000 $810,000 December 31, 2018 $3,232,000 $887,000 first first not As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2019 2018. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. In 2019, six June 30, 2019 not December 31, 2019, $662,000 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No December 31, 2019 2018. $108,000 $686,000, not December 31, 2019 December 31, 2018, The following table reflects the changes in our customer contract liabilities for the year ended December 31, 2019 December 31, December 31, 2019 2018 Change Customer contracts liabilities: Marketing programs $ 108 $ 639 $ (531 ) Other - 47 (47 ) Total $ 108 $ 686 $ (578 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2019 2018, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $486,000 $0 December 31, 2019 2018, December 31, 2019 2018, $143,000 $0, no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated statement of operations for the year ended December 31, 2018 December 31, 2018 For the year ended December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Revenue $ 18,517 $ 17,780 $ 737 (1) Cost of revenue $ 11,197 $ 11,209 $ (12 ) (2) Gross profit $ 7,320 $ 6,571 $ 749 (3) Loss from operations $ (44,965 ) $ (45,714 ) $ 749 (3) Comprehensive and net loss $ (49,981 ) $ (50,730 ) $ 749 (3) Net loss per share: Basic and diluted $ (160.92 ) $ (163.33 ) $ 2.41 Weighted average shares 310,589 310,589 ( 1 Change relates to revenue from extended assurance warranties for which no 606. ( 2 Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606. ( 3 Change relates to the net gain adjustment on the adoption of ASC 606. As of December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheets Liabilities Accrued liabilities $ 6,766 $ 7,014 $ (248 ) (1) Other noncurrent liabilities $ 634 $ 1,313 $ (679 ) (2) Equity Accumulated deficit $ (155,385 ) $ (156,311 ) $ 926 (3) ( 1 Change relates to the current portion of deferred revenue in connection with the extended warranties not 606, 606. ( 2 Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not 606. ( 3 Change relates to $177,000 606 $749,000 December 31, 2018. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). Year Ended December 31, 2019 2018 United States $ 3,672 13,606 Asia Pacific 2,349 2,891 Europe and Middle East 254 1,369 Canada 277 563 Latin America 15 51 Other - 37 Total $ 6,567 $ 18,517 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2019 2018, no Product Warranty The Company’s products are generally subject to warranties between one three not Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2019 2018. Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2019 2018. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12 Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2019 2018, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2019 2018 Convertible preferred stock: Series A convertible preferred stock 1,852,173 (a) - Series B convertible preferred stock 31,678 (b) - Warrants to purchase common stock 24,737,618 6,408 Stock options to purchase common stock 10,087,678 40,195 Restricted common stock awards 2,620 575 (a) Each share of Series A preferred stock is convertible at any time at the holder's option into one (b) Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1 653.59 $1,000 $1.53 not Other Recently Issued and Adopted Accounting Standards In June 2018, 2018 07, 718 718 718 December 15, 2018, January 1, 2019 not In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no December 31, 2019 2018. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of December 31, 2019 2018 There were no

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, Net Property and equipment, net, consisted of the following as of December 31, 2019 2018 Life December 31, (in years) 2019 2018 Medical equipment 5 $ 2,933 $ 3,571 Rental program equipment 5 1,619 - Computer equipment 3 243 309 Leasehold Improvements 3 384 403 Furniture and fixtures 7 123 121 Software 3 25 25 5,327 4,429 Less: Accumulated depreciation and amortization (2,281 ) (1,513 ) Property and equipment, net $ 3,046 $ 2,916 Depreciation and amortization expense for the years ended December 31, 2019 2018 $1,177,000 $786,000,

Note 5 - Investment in Limited

Note 5 - Investment in Limited Liability Company	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	5. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not December 31, 2019 2018, 300 3,300 $26,000 $327,000, $27,000 $337,000 December 31, 2019 2018, In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not December 31, 2019, 7% three December 31, 2019 2018, $627,000 $657,000 In February 2019, no

Note 6 - Accrued Liabilities

Note 6 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Liabilities Accrued liabilities consisted of the following as of December 31, 2019 2018 December 31, 2019 2018 Accrued payroll and other related expenses $ 839 $ 877 Accrued bonuses 726 837 Deferred revenue - subscription rental program 662 - Accrued professional fees 592 978 Accrued inventory purchases 474 - Accrued interest 440 683 Accrued sales commission 281 1,743 Current operating lease liabilities 268 - Customer contracts liabilities 108 686 Travel and entertainment 78 280 Other accruals 230 682 Total accrued liabilities $ 4,698 $ 6,766

Note 7 - Note Payable

Note 7 - Note Payable	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Note Payable On May 22, 2017, December 12, 2017 November 29, 2018 ( “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 2017 may In connection with the 2017 two 10 2,220 $950.00 12 Under the 2017 six four 2017 12.5%, 4.0% December 31, 2019 2018, $1,226,000 $1,256,000, 5.0% As security for its obligations under the 2017 The terms of the 2017 $2,000,000 2022, not 2.0 2017 On November 12, 2019, 2017 $28,981,000 $31,300,000. 31,300 9,893,776 5 120% $1.53 $1.836 11 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23 rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company’s ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% 25%. As of December 31, 2019, As of December 31, 2019, 2018, $3,983,000 $30,528,000 The Company accounted for the changes in the 2017 31,300 9,893,776 November 26, 2019 1 $0.869 November 26, 2019); ( 2 73%; 3 2 4 1.58%. $1,023.23 $32,027,000. $3,502,000 11 $6,705,000. As of December 31, 2019, Year Ending December 31, 2020 $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,997 ) Present value of obligations 3,995 Less: Unamortized debt discount (12 ) Note payable, noncurrent portion $ 3,983

Note 8 - Leases

Note 8 - Leases	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. In January 2012, March 2012 April 2018. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 The office rent expense for the year ended December 31, 2018 $358,000. In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at December 31, 2019 January 1, 2019 ( December 31, January 1, 2019 2019 Assets: Operating lease right-of-use assets $ 395 $ 629 Liabilities: Current operating lease liabilities $ 268 $ 230 Noncurrent operating lease liabilities 132 399 $ 400 $ 629 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheet. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheet. The operating leases expense for the year ended December 31, 2019 $301,000. As of December 31, 2019, Year Ending December 31, 2020 $ 303 2021 137 Total lease payments 440 Less: Amount representing interest (40 ) Present value of lease liabilities $ 400 The weighted average remaining lease term was approximately 17 December 31, 2019. December 31, 2019 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of December 31, 2019, Year Ending December 31, 2020 $ 662 Thereafter - Total $ 662 As of December 31, 2019, $1,117,000 December 31, 2019 $121,000.

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not Legal Proceedings In December 2018, On June 4, 2018, Under the terms of the Settlement Agreement, the Company received an initial monetary payment to settle the litigation and past claims and an on-going royalty for future sales. Viveve granted to ThermiGen a non-exclusive, non-transferable license to use the Company’s U.S. patent for the then current version of ThermiGen’s ThermiVa system (which includes RF generators and consumables). The Company has recorded the monetary payment as a gain on litigation settlement in selling, general and administrative expenses on the consolidated statements of operations during the year ended December 31, 2018.

Note 10 - Preferred Stock

Note 10 - Preferred Stock	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Preferred Stock [Text Block]	10. Preferred Stock In connection with the closing of the public offering, on November 26, 2019, With certain exceptions, as described in the Series A Certificate of Designation, the shares of Series A preferred stock have no Each share of Series A convertible preferred stock is convertible at any time at the holder’s option into one In November December 2019, 600,000 3,021,237 December 31, 2019, 1,852,173 15 In connection with the CRG debt conversion, on November 26, 2019, 12.5% December 31, 2019, 378 $2,400 December 31, 2019 February 2020. no The Series B convertible preferred stock provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company’s organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. The fair value of the Series B convertible preferred stock was determined in connection with the CRG debt conversion as part of the accounting for that transaction as a troubled debt restructuring. (See Note 7 November 26, 2019, $1,023.23 $32,027,000 31,300 Under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not

Note 11 - Common Stock

Note 11 - Common Stock	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Common Stock In November 2019, “November 2019 $11,500,000, $9,952,000. The offering comprised of: ( 1 $1.55 one one $1.55 first one $1.55 fifth 2 $1.55 one one one $1.55 first one $1.55 fifth The securities comprising the units were immediately separable and were issued separately. A total of 1,945,943 5,473,410 7,419,353 7,419,353 In November December 2019, 600,000 3,021,237 ATM Equity Offerings Through the August 2019 may $6,760,000 $6,760,000 August 2019 September 2019. December 31, 2019, 1,004,171 August 2019 $6,322,000. In August 2019, November 2017 $25,000,000 December 31, 2019, zero November 2017 December 31, 2018 2,771 November 2017 $1,193,000. November 2017 August 2019, 3,364 $1,318,000. Restricted Common Shares In December 2019, 30,675 $25,000. In October 2019, 7,740 $25,000. In March 2019, 274 $25,000. 2018 In December 2018, “December 2018 147,285 $22,093,000. $20,384,000. In June 2018, 1,000 $2.56 $256,000. In February 2018, February 2018 115,000 $34,500,000. $32,214,000. Warrants for Common Stock As of December 31, 2019, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 1.55 7,419,353 November 2019 Common Shares November 26, 2024 $ 1.55 7,419,353 November 2019 Common Shares November 26, 2024 $ 1.84 9,893,776 24,737,618 As of December 31, 2018, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 424.00 859 October 2014 Common Shares October 13, 2019 $ 424.00 288 November 2014 Common Shares November 12, 2019 $ 424.00 125 February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 6,408 In connection with the November 2019 7,419,353 7,419,353 one $1.55 first one $1.55 fifth one one $1.55 one five $1.55 $1,210,000 0%, 91.1%, 1.59% one $2,871,000 0%, 68.8%, 1.58% five $4,081,000 November 2019 In connection with the CRG Debt Conversion, CRG received warrants exercisable for 9,893,776 15% November 2019 five 120% $1.53 $1.836 $3,502,000 0%, 68.8%, 1.58% five In connection with the 2017 2,220, $950 ten $940,000 0%, 55.1%, 2.25% ten $790,000, December 31, 2019 2018, $352,000 $325,000, December 31, 2019, $12,000. No December 31, 2019 2018, No December 31, 2019 2018. A total of 1,272 December 31, 2019. No December 31, 2018. The stock-based compensation expense related to warrants issued was zero December 31, 2019 2018,

Note 12 - Summary of Stock Opti

Note 12 - Summary of Stock Options	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of December 31, 2019, 2006 104 no $992.00 3.1 The 2013 2013 2013 may may may 2013 may not 10 may four may 424 10% no 110% not five On August 22, 2016, 2013 first January, 2013 4% In December 2017, 2018 2013 40,000 49,140 January 1, 2018. In January 2019, 2019 2013 20,431 49,140 69,571 January 1, 2019. In September 2019, 2013 18% 1 $5.0 2 December 31, 2019. 2013 11,872,531 November 26, 2019. As of December 31, 2019, 2013 10,087,574 1,798,337 $2.21 9.9 Activity under the 2006 2013 Year Ened December 31, 2019 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, January 1, 2018 26,903 $ 579.81 8.6 $ 249,154 Options granted 23,542 $ 351.81 Options exercised - $ - Options canceled (10,301 ) $ 548.13 Options outstanding, December 31, 2018 40,144 $ 455.68 7.4 $ - Options granted 10,065,844 $ 1.14 Options exercised - Options canceled (18,310 ) $ 403.31 Options outstanding, December 31, 2019 10,087,678 $ 2.22 9.9 $ 3,928,715 Vested and exercisable and expected to vest, end of period 8,966,825 $ 2.36 9.9 $ 3,490,722 Vested and exercisable, end of period 222,582 $ 41.49 9.5 $ 77,540 The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of December 31, 2019. The options outstanding and exercisable as of December 31, 2019 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2019 Price Term (Years) December 31, 2019 Price $0.86 - $0.89 10,042,500 $ 0.87 9.9 198,312 $ 0.87 $38.00 - $58.00 1,650 $ 55.42 9.4 - $ - $100.00 - $197.00 22,385 $ 140.23 8.1 9,141 $ 144.93 $202.00 - $283.00 775 $ 252.06 8.0 355 $ 255.75 $311.00 - $382.00 3,833 $ 355.39 6.0 2,423 $ 362.12 $430.00 - $497.00 7,870 $ 453.47 6.4 5,066 $ 454.44 $501.00 - $567.00 4,215 $ 536.47 5.7 3,258 $ 535.73 $600.00 - $661.00 2,372 $ 601.29 3.6 2,352 $ 600.78 $700.00 - $792.00 1,974 $ 768.12 6.7 1,571 $ 768.19 $992.00 - $992.00 104 $ 992.00 3.1 104 $ 992.00 Total: 10,087,678 $ 2.22 9.9 222,582 $ 41.49 Stock Option Modifications On May 30, 2018, December 31, 2019. May 30, 2018, six three one $97,000 Restricted Stock Awards In July 2019, 378 2013 $38.08 378 In June 2019, 250 June 2018. In April 2019, 525 2013 $91.00 525 In January 2019, 3,625 2013 2018 2018 50% 50% December 31, 2019, 1,255 December 31, 2019, zero As of December 31, 2019, 2,640 In July 2019, 378 2013 $38.08 378 In April 2019, 525 2013 $91.00 525 In December 2018, 407 2013 $105.00 407 In October 2018, 178 2013 $248.00 178 In July 2018, 181 2013 $263.00 182 In June 2018, 500 $358.00 two December 31, 2019, 250 In April 2018, 144 2013 $344.00 144 In January 2018, 943 2013 $519.00 94 In January 2018, 250 $497.00 one December 31, 2018, 250 2017 In August 2017, 2017 “2017 may 200 2017 85% first three first 2017 October 1, 2017 December 31, 2017. The second 2017 January 1, 2018 March 31, 2018, 198 March 29, 2018 $311.10. The third 2017 April 1, 2018 June 30, 2018, 243 June 29, 2018 $231.20. The fourth 2017 July 1, 2018 September 30, 2018, 274 September 28, 2018 $223.55. The fifth 2017 October 1, 2018 December 31, 2018, 494 December 31, 2018 $89.25. The sixth 2017 January 1, 2019 March 31, 2019, 429 March 29, 2019 $79.88. The seventh 2017 April 1, 2019 June 30, 2019, 602 June 28, 2019 $32.30. The eighth 2017 July 1, 2019 September 30, 2019, 200 September 30, 2019 $3.75. The ninth 2017 October 1, 2019 December 31, 2019, 300 December 31, 2019 $1.07. During the years ended December 31, 2019 2018, 2017 1,531 1,209 $233,000 $56,000, As of December 31, 2019, 2017 1,092 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Year Ended December 31, 2019 2018 Expected term (in years) 0.25 0.25 Average volatility 87% 72% Risk-free interest rate 2.29% 1.92% Dividend yield 0% 0% The weighted average grant date fair value of the purchase rights issued under the 2017 December 31, 2019 2018 $22.75 $89.00 Stock-Based Compensation During the years ended December 31, 2019 2018, 9,528,869 21,419 $0.73 $224.35 no December 31, 2019 2018. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2019 2018 Expected term (in years) 6 5 Average volatility 70% 73% Risk-free interest rate 1.62% 2.65% Dividend yield 0% 0% During the years ended December 31, 2019 2018, 536,975 2,123 $0.61 $162.17 no December 31, 2019 2018. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2019 2018 Expected term (in years) 6 9 Average volatility 70% 69% Risk-free interest rate 1.69% 2.69% Dividend yield 0% 0% Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the consolidated statements of operations for the years ended December 31, 2019 2018 Year Ended December 31, 2019 2018 Cost of revenue $ 135 $ 69 Research and development 192 328 Selling, general and administrative 2,073 2,638 Total $ 2,400 $ 3,035 As of December 31, 2019, $7,640,000. 3.3

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes No no A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2019 2018 Income tax provision (benefit) at statutory rate (21 )% (21 )% State income taxes, net of federal benefit (4 )% (4 )% Change in valuation allowance (39 )% 23 % Debt restructuring 6 % 0 % Limitation on net operating loss and credit carryovers 56 % 0 % Other 2 % 2 % Effective tax rate 0 % 0 % The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands): December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 16,688 $ 31,759 Capitalized start up costs 3,225 3,555 Research and development credits 527 951 Accruals and reserves 532 1,272 Fixed assets and depreciation 128 69 Total deferred tax assets 21,100 37,606 Deferred tax liabilities: Valuation allowance (21,100 ) (37,606 ) Net deferred tax assets $ - $ - The Company has recorded a full valuation allowance for its deferred tax assets based on its past losses and the uncertainty regarding the ability to project future taxable income. The valuation allowance decreased by approximately $16,506,000 $11,667,000 December 31, 2019 2018, As of December 31, 2019, $77,333,000 $6,171,000, not 2028. The Company also has California research and development tax credits of approximately $742,000. no Utilization of the NOL and research and development credit carryforwards may 382 1986, may 382, 50 three November 2019, no As of December 31, 2019, not A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2019 2018 Balance at the beginning of the year $ 450 $ 397 Additions (deletions) based upon tax positions related to the current year (227 ) 53 Balance at the end of the year $ 223 $ 450 If the ending balance of $223,000 December 31, 2019 none not twelve may The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception remain open to examination due to the carryover of unused net operating losses and tax credits.

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	14. Related Party Transactions In June 2006, October 4, 2007. 300 December 31, 2019, 855 375 $4,889,000 $10,150,000 December 31, 2019 2018, In August 2017, February 2019, no

Note 15 - Segments and Geograph

Note 15 - Segments and Geographic Information	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. S egments and Geographic Information The Company’s long-lived assets by geographic area were as follows (in thousands): December 31, 2019 2018 United States $ 2,818 $ 2,851 Asia Pacific 64 24 Canada 142 28 Latin America - 5 Europe 22 8 Total $ 3,046 $ 2,916 Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at each balance sheet date.

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	1 6 . Subsequent Events In January 2020, 2020 2013 2,639,926 11,872,531 14,512,457 January 1, 2020. In January February 2020, 1,183,151 669,022 February 19, 2020, no In February 2020, 1,026,240 $1,591,000. In February 2020, 45,473 $70,000.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reserve Stock Split, Policy [Policy Text Block]	Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Changes in Accounting Policies, Policy [Policy Text Block]	Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard-Leases The Company adopted FASB’s Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2019, one 16% December 31, 2018, one 21% There were no 10% December 31, 2019 2018. As of December 31, 2019, two 49% December 31, 2018, three 54%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $407,000 $284,000 December 31, 2019 2018, During the year ended December 31, 2019, $1,028,000 no December 31, 2018.
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2019 $4,051,000 $810,000 December 31, 2018 $3,232,000 $887,000 first first not As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2019 2018.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not
Revenue from Contract with Customer [Policy Text Block]	Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. In 2019, six June 30, 2019 not December 31, 2019, $662,000 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No December 31, 2019 2018. $108,000 $686,000, not December 31, 2019 December 31, 2018, The following table reflects the changes in our customer contract liabilities for the year ended December 31, 2019 December 31, December 31, 2019 2018 Change Customer contracts liabilities: Marketing programs $ 108 $ 639 $ (531 ) Other - 47 (47 ) Total $ 108 $ 686 $ (578 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2019 2018, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $486,000 $0 December 31, 2019 2018, December 31, 2019 2018, $143,000 $0, no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated statement of operations for the year ended December 31, 2018 December 31, 2018 For the year ended December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Revenue $ 18,517 $ 17,780 $ 737 (1) Cost of revenue $ 11,197 $ 11,209 $ (12 ) (2) Gross profit $ 7,320 $ 6,571 $ 749 (3) Loss from operations $ (44,965 ) $ (45,714 ) $ 749 (3) Comprehensive and net loss $ (49,981 ) $ (50,730 ) $ 749 (3) Net loss per share: Basic and diluted $ (160.92 ) $ (163.33 ) $ 2.41 Weighted average shares 310,589 310,589 ( 1 Change relates to revenue from extended assurance warranties for which no 606. ( 2 Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606. ( 3 Change relates to the net gain adjustment on the adoption of ASC 606. As of December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheets Liabilities Accrued liabilities $ 6,766 $ 7,014 $ (248 ) (1) Other noncurrent liabilities $ 634 $ 1,313 $ (679 ) (2) Equity Accumulated deficit $ (155,385 ) $ (156,311 ) $ 926 (3) ( 1 Change relates to the current portion of deferred revenue in connection with the extended warranties not 606, 606. ( 2 Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not 606. ( 3 Change relates to $177,000 606 $749,000 December 31, 2018. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). Year Ended December 31, 2019 2018 United States $ 3,672 13,606 Asia Pacific 2,349 2,891 Europe and Middle East 254 1,369 Canada 277 563 Latin America 15 51 Other - 37 Total $ 6,567 $ 18,517 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2019 2018, no
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to warranties between one three not
Advertising Cost [Policy Text Block]	Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2019 2018.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2019 2018. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2019 2018,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2019 2018 Convertible preferred stock: Series A convertible preferred stock 1,852,173 (a) - Series B convertible preferred stock 31,678 (b) - Warrants to purchase common stock 24,737,618 6,408 Stock options to purchase common stock 10,087,678 40,195 Restricted common stock awards 2,620 575 (a) Each share of Series A preferred stock is convertible at any time at the holder's option into one (b) Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1 653.59 $1,000 $1.53 not
New Accounting Pronouncements, Policy [Policy Text Block]	Other Recently Issued and Adopted Accounting Standards In June 2018, 2018 07, 718 718 718 December 15, 2018, January 1, 2019 not In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Cumulative Effect of Adjustments for New Accounting Pronouncements on Balance Sheet [Table Text Block]	Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463
Contract with Customer, Asset and Liability [Table Text Block]	December 31, December 31, 2019 2018 Change Customer contracts liabilities: Marketing programs $ 108 $ 639 $ (531 ) Other - 47 (47 ) Total $ 108 $ 686 $ (578 )
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	For the year ended December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Revenue $ 18,517 $ 17,780 $ 737 (1) Cost of revenue $ 11,197 $ 11,209 $ (12 ) (2) Gross profit $ 7,320 $ 6,571 $ 749 (3) Loss from operations $ (44,965 ) $ (45,714 ) $ 749 (3) Comprehensive and net loss $ (49,981 ) $ (50,730 ) $ 749 (3) Net loss per share: Basic and diluted $ (160.92 ) $ (163.33 ) $ 2.41 Weighted average shares 310,589 310,589 As of December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheets Liabilities Accrued liabilities $ 6,766 $ 7,014 $ (248 ) (1) Other noncurrent liabilities $ 634 $ 1,313 $ (679 ) (2) Equity Accumulated deficit $ (155,385 ) $ (156,311 ) $ 926 (3)
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2019 2018 United States $ 3,672 13,606 Asia Pacific 2,349 2,891 Europe and Middle East 254 1,369 Canada 277 563 Latin America 15 51 Other - 37 Total $ 6,567 $ 18,517
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2019 2018 Convertible preferred stock: Series A convertible preferred stock 1,852,173 (a) - Series B convertible preferred stock 31,678 (b) - Warrants to purchase common stock 24,737,618 6,408 Stock options to purchase common stock 10,087,678 40,195 Restricted common stock awards 2,620 575

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	Life December 31, (in years) 2019 2018 Medical equipment 5 $ 2,933 $ 3,571 Rental program equipment 5 1,619 - Computer equipment 3 243 309 Leasehold Improvements 3 384 403 Furniture and fixtures 7 123 121 Software 3 25 25 5,327 4,429 Less: Accumulated depreciation and amortization (2,281 ) (1,513 ) Property and equipment, net $ 3,046 $ 2,916

Note 6 - Accrued Liabilities (T

Note 6 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2019 2018 Accrued payroll and other related expenses $ 839 $ 877 Accrued bonuses 726 837 Deferred revenue - subscription rental program 662 - Accrued professional fees 592 978 Accrued inventory purchases 474 - Accrued interest 440 683 Accrued sales commission 281 1,743 Current operating lease liabilities 268 - Customer contracts liabilities 108 686 Travel and entertainment 78 280 Other accruals 230 682 Total accrued liabilities $ 4,698 $ 6,766

Note 7 - Note Payable (Tables)

Note 7 - Note Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2020 $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,997 ) Present value of obligations 3,995 Less: Unamortized debt discount (12 ) Note payable, noncurrent portion $ 3,983

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Lessee, Lease Assets and Liabilities [Table Text Block]	December 31, January 1, 2019 2019 Assets: Operating lease right-of-use assets $ 395 $ 629 Liabilities: Current operating lease liabilities $ 268 $ 230 Noncurrent operating lease liabilities 132 399 $ 400 $ 629
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2020 $ 303 2021 137 Total lease payments 440 Less: Amount representing interest (40 ) Present value of lease liabilities $ 400
Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block]	Year Ending December 31, 2020 $ 662 Thereafter - Total $ 662

Note 11 - Common Stock (Tables)

Note 11 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 1.55 7,419,353 November 2019 Common Shares November 26, 2024 $ 1.55 7,419,353 November 2019 Common Shares November 26, 2024 $ 1.84 9,893,776 24,737,618 Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 424.00 859 October 2014 Common Shares October 13, 2019 $ 424.00 288 November 2014 Common Shares November 12, 2019 $ 424.00 125 February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 6,408

Note 12 - Summary of Stock Op_2

Note 12 - Summary of Stock Options (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Year Ened December 31, 2019 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, January 1, 2018 26,903 $ 579.81 8.6 $ 249,154 Options granted 23,542 $ 351.81 Options exercised - $ - Options canceled (10,301 ) $ 548.13 Options outstanding, December 31, 2018 40,144 $ 455.68 7.4 $ - Options granted 10,065,844 $ 1.14 Options exercised - Options canceled (18,310 ) $ 403.31 Options outstanding, December 31, 2019 10,087,678 $ 2.22 9.9 $ 3,928,715 Vested and exercisable and expected to vest, end of period 8,966,825 $ 2.36 9.9 $ 3,490,722 Vested and exercisable, end of period 222,582 $ 41.49 9.5 $ 77,540
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2019 Price Term (Years) December 31, 2019 Price $0.86 - $0.89 10,042,500 $ 0.87 9.9 198,312 $ 0.87 $38.00 - $58.00 1,650 $ 55.42 9.4 - $ - $100.00 - $197.00 22,385 $ 140.23 8.1 9,141 $ 144.93 $202.00 - $283.00 775 $ 252.06 8.0 355 $ 255.75 $311.00 - $382.00 3,833 $ 355.39 6.0 2,423 $ 362.12 $430.00 - $497.00 7,870 $ 453.47 6.4 5,066 $ 454.44 $501.00 - $567.00 4,215 $ 536.47 5.7 3,258 $ 535.73 $600.00 - $661.00 2,372 $ 601.29 3.6 2,352 $ 600.78 $700.00 - $792.00 1,974 $ 768.12 6.7 1,571 $ 768.19 $992.00 - $992.00 104 $ 992.00 3.1 104 $ 992.00 Total: 10,087,678 $ 2.22 9.9 222,582 $ 41.49
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2019 2018 Expected term (in years) 6 5 Average volatility 70% 73% Risk-free interest rate 1.62% 2.65% Dividend yield 0% 0% Year Ended December 31, 2019 2018 Expected term (in years) 6 9 Average volatility 70% 69% Risk-free interest rate 1.69% 2.69% Dividend yield 0% 0%
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2019 2018 Cost of revenue $ 135 $ 69 Research and development 192 328 Selling, general and administrative 2,073 2,638 Total $ 2,400 $ 3,035
2017 Employee Stock Purchase Plan [Member]
Notes Tables
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2019 2018 Expected term (in years) 0.25 0.25 Average volatility 87% 72% Risk-free interest rate 2.29% 1.92% Dividend yield 0% 0%

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2019 2018 Income tax provision (benefit) at statutory rate (21 )% (21 )% State income taxes, net of federal benefit (4 )% (4 )% Change in valuation allowance (39 )% 23 % Debt restructuring 6 % 0 % Limitation on net operating loss and credit carryovers 56 % 0 % Other 2 % 2 % Effective tax rate 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 16,688 $ 31,759 Capitalized start up costs 3,225 3,555 Research and development credits 527 951 Accruals and reserves 532 1,272 Fixed assets and depreciation 128 69 Total deferred tax assets 21,100 37,606 Deferred tax liabilities: Valuation allowance (21,100 ) (37,606 ) Net deferred tax assets $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2019 2018 Balance at the beginning of the year $ 450 $ 397 Additions (deletions) based upon tax positions related to the current year (227 ) 53 Balance at the end of the year $ 223 $ 450

Note 15 - Segments and Geogra_2

Note 15 - Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	December 31, 2019 2018 United States $ 2,818 $ 2,851 Asia Pacific 64 24 Canada 142 28 Latin America - 5 Europe 22 8 Total $ 3,046 $ 2,916

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Nov. 12, 2019	Aug. 16, 2019	Feb. 12, 2018	Nov. 08, 2017	Dec. 31, 2019	Nov. 30, 2019	Aug. 31, 2019	Dec. 31, 2018	Feb. 28, 2018	Nov. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Shares Issued, Price Per Share													$ 2.56
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					24,737,618			6,408			24,737,618	6,408
Debt Conversion, Converted Instrument, Amount											$ 35,529,000
Proceeds from Issuance of Common Stock											16,274,000	53,792,000
Retained Earnings (Accumulated Deficit), Ending Balance					$ (197,911,000)			$ (155,385,000)			(197,911,000)	(155,385,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance					13,308,000			$ 29,523,000			13,308,000	29,523,000		$ 20,730,000
Working Capital					$ 15,883,000						15,883,000
Net Cash Provided by (Used in) Operating Activities, Total											$ (31,236,000)	$ (43,090,000)
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount	$ 28,981,000
Debt Conversion, Converted Instrument, Amount	$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued	31,300
Series A Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted					3,021,237	600,000
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate	$ 1.53
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate	$ 1.836
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion					1	1				1	1
Preferred Stock, Shares Outstanding, Ending Balance					1,852,173			0			1,852,173	0
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.55	$ 1.55				$ 1.55	$ 1.55
Warrants and Rights Outstanding, Term						1 year				1 year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					7,419,353	7,419,353				7,419,353	7,419,353
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.55	$ 1.55				$ 1.55	$ 1.55
Warrants and Rights Outstanding, Term						5 years				5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					7,419,353	7,419,353				7,419,353	7,419,353
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.84						$ 1.84
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	9,893,776				9,893,776						9,893,776
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate	120.00%
Class A Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.55				$ 1.55
Warrants and Rights Outstanding, Term						1 year				1 year
Class A Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.55				$ 1.55
Warrants and Rights Outstanding, Term						5 years				5 years
Class B Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.55				$ 1.55
Warrants and Rights Outstanding, Term						1 year				1 year
Class B Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.55				$ 1.55
Warrants and Rights Outstanding, Term						5 years				5 years
November 2019 Offering [Member]
Proceeds from Issuance or Sale of Equity, Total						$ 11,500,000
Proceeds From Issuance of Common Stock, Net						$ 9,952,000
November 2019 Offering [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues						5,473,410
November 2019 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share						$ 1.55				$ 1.55
Common Shares Per Unit						1				1
November 2019 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share						$ 1.55				$ 1.55
Series A Convertible Preferred Stock Per Unit						1				1
November 2019 Offering [Member] | Class B Units [Member] | Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion						1				1
November 2019 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues						1,945,943				1,945,943	1,945,943
August 2019 ATM Facility [Member]
Proceeds From Issuance of Common Stock, Net											$ 6,322,000
Stock Issued During Period, Shares, New Issues											1,004,171
Aggregate Offering Price		$ 6,760,000					$ 6,760,000
August 2019 ATM Facility [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues											1,004,171
November 2017 ATM Facility [Member]
Proceeds From Issuance of Common Stock, Net						$ 1,193,000	$ 1,318,000					$ 1,193,000
Stock Issued During Period, Shares, New Issues						2,771	3,364				0	2,771
Aggregate Offering Price				$ 25,000,000			$ 25,000,000
November 2017 ATM Facility [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues												2,771
December 2018 Offering [Member]
Proceeds From Issuance of Common Stock, Net								$ 20,384,000
Stock Issued During Period, Shares, New Issues								147,285
Proceeds from Issuance of Common Stock								$ 22,093,000
December 2018 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues												147,285
February 2018 Offering [Member]
Proceeds From Issuance of Common Stock, Net			$ 32,214,000						$ 32,214,000
Stock Issued During Period, Shares, New Issues									115,000
Proceeds from Issuance of Common Stock			$ 34,500,000						$ 34,500,000
February 2018 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues												115,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Sep. 18, 2019USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Nov. 30, 2019shares	Jan. 01, 2019USD ($)
Payments for Fractional Shares of Reverse Stock Split	$ 6,000
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized | shares		75,000,000	75,000,000	75,000,000
Operating Lease, Right-of-Use Asset			$ 395,000			$ 629,000
Number of Financial Institutions			1
Accounts Receivable, Allowance for Credit Loss, Ending Balance		$ 284,000	$ 407,000	$ 284,000
Accounts Receivable, Allowance for Credit Loss, Writeoff			1,028,000	0
Inventory, Finished Goods, Net of Reserves		3,232,000	4,051,000	3,232,000
Inventory, Raw Materials, Net of Reserves		887,000	810,000	887,000
Deferred Income			662,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total		0	0	0
Contract with Customer, Liability, Total		686,000	108,000	686,000
Capitalized Contract Cost, Net, Total		0	486,000	0
Capitalized Contract Cost, Amortization			143,000	0
Capitalized Contract Cost, Impairment Loss			0
Retained Earnings (Accumulated Deficit), Ending Balance		(155,385,000)	(197,911,000)	(155,385,000)
Gross Profit, Total			1,016,000	7,320,000
Equity Method Investment, Other than Temporary Impairment		0	$ 0
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion | shares			1		1
Series B Preferred Stock [Member]
Conversion of Stock Exchange Ratio			653.59
Preferred Stock, Liquidation Preference Per Share | $ / shares			$ 1,000
Conversion of Stock, Conversion Rate | $ / shares			$ 1.53
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance		$ 177,000		177,000
Gross Profit, Total				$ 749,000
Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Warranty Period			1 year
Maximum [Member]
Property, Plant and Equipment, Useful Life			7 years
Warranty Period			3 years
Medical Equipment, Sales Demos [Member]
Property, Plant and Equipment, Useful Life			5 years
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Number of Customers			1	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage			16.00%	21.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers			2	3
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage			49.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage				54.00%
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Total			$ 400,000			$ 629,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	100

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Cumulative Effect of Adjustments for New Accounting Pronouncements on Consolidated Balance Sheet (Details) - USD ($) $ in Thousands		Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Other assets		$ 526	$ 800	$ 171
Total assets		26,977	47,463	46,834
Accrued liabilities		4,698	6,996	6,766
Total current liabilities		6,306	10,990	10,760
Other noncurrent liabilities		167	1,033	634
Total liabilities		10,456	42,551	41,922
Total liabilities and stockholders' equity		$ 26,977	47,463	$ 46,834
Accounting Standards Update 2016-02 [Member]
Other assets	[1]		629
Total assets	[1]		629
Accrued liabilities	[2]		230
Total current liabilities	[2]		230
Other noncurrent liabilities	[2]		399
Total liabilities	[2]		629
Total liabilities and stockholders' equity	[2]		$ 629
[1]	Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent.
[2]	Represents recognition of operating lease liabilities.

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Customer contract liabilities	$ 108,000	$ 686,000
Change in customer contract liabilities	(578,000)
Marketing Programs [Member]
Customer contract liabilities	108,000	639,000
Change in customer contract liabilities	(531,000)
Product and Service, Other [Member]
Customer contract liabilities		$ 47,000
Change in customer contract liabilities	$ (47,000)

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Impact of New Standard on Consolidated Balance Sheet and Consolidated Statements of Operations (Details) - USD ($)		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019
Revenue		$ 6,567,000	$ 18,517,000
Cost of revenue		5,551,000	11,197,000
Gross profit		1,016,000	7,320,000
Loss from operations		(30,679,000)	(44,965,000)
Comprehensive and net loss		$ (42,526,000)	$ (49,981,000)
Basic and diluted (in dollars per share)		$ (34.39)	$ (160.92)
Weighted average shares (in shares)		1,247,768	310,589
Accrued liabilities		$ 4,698,000	$ 6,766,000	$ 6,996,000
Other noncurrent liabilities		167,000	634,000	$ 1,033,000
Accumulated deficit		$ (197,911,000)	(155,385,000)
Accounting Standards Update 2014-09 [Member]
Gross profit			749,000
Accumulated deficit			177,000
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenue			17,780,000
Cost of revenue			11,209,000
Gross profit			6,571,000
Loss from operations			(45,714,000)
Comprehensive and net loss			$ (50,730,000)
Basic and diluted (in dollars per share)			$ (163.33)
Weighted average shares (in shares)			310,589
Accrued liabilities			$ 7,014,000
Other noncurrent liabilities			1,313,000
Accumulated deficit			(156,311,000)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenue	[1]		737,000
Cost of revenue	[2]		(12,000)
Gross profit	[3]		749,000
Loss from operations	[3]		749,000
Comprehensive and net loss	[3]		$ 749,000
Basic and diluted (in dollars per share)			$ 2.41
Weighted average shares (in shares)
Accrued liabilities	[4]		$ (248,000)
Other noncurrent liabilities	[5]		(679,000)
Accumulated deficit	[6]		$ 926,000
[1]	Change relates to revenue from extended assurance warranties for which no deferral is required on the adoption of ASC 606.
[2]	Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606.
[3]	Change relates to the net gain adjustment on the adoption of ASC 606.
[4]	Change relates to the current portion of deferred revenue in connection with the extended warranties not required to be recorded under ASC 606, partially offset by future costs associated with extended warranties required to be recorded on the adoption of ASC 606.
[5]	Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not required to be recorded under ASC 606.
[6]	Change relates to $177,000 cumulative effect adjustment on the adoption of ASC 606 and the net gain adjustment of $749,000 for the year ended December 31, 2018.

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue	$ 6,567	$ 18,517
UNITED STATES
Revenue	3,672	13,606
Asia Pacific [Member]
Revenue	2,349	2,891
Europe And Middle East [Member]
Revenue	254	1,369
CANADA
Revenue	277	563
Latin America [Member]
Revenue	15	51
Other [Member]
Revenue		$ 37

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2019		Dec. 31, 2018
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	1,852,173	[1]
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	31,678	[2]
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	24,737,618		6,408
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	10,087,678		40,195
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	2,620		575
[1]	Each share of Series A preferred stock is convertible at any time at the holder's option into one share of common stock.
[2]	Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-653.59 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $1.53 per share.

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Depreciation, Total	$ 1,177,000	$ 786,000

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Equipment, Furniture, and Leasehold Improvements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross	$ 5,327	$ 4,429
Less: Accumulated depreciation and amortization	(2,281)	(1,513)
Property and equipment, net	$ 3,046	2,916
Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Property and equipment, gross	$ 2,933	3,571
Rental Program Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Property and equipment, gross	$ 1,619
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Property and equipment, gross	$ 243	309
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	3 years
Property and equipment, gross	$ 384	403
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	7 years
Property and equipment, gross	$ 123	121
Software [Member]
Property, Plant and Equipment, Useful Life	3 years
Property and equipment, gross	$ 25	$ 25

Note 5 - Investment in Limite_2

Note 5 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Income (Loss) from Equity Method Investments, Total		$ (627,000)	$ (657,000)
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		7.00%
Income (Loss) from Equity Method Investments, Total		$ 627,000	$ 657,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		300	3,300
Unrecorded Unconditional Purchase Obligation, Purchases		$ 26,000	$ 327,000
Payments for Purchase of Products		$ 27,000	$ 337,000
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 6 - Accrued Liabilities -

Note 6 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Accrued payroll and other related expenses	$ 839		$ 877
Accrued bonuses	726		837
Deferred revenue - subscription rental program	662
Accrued professional fees	592		978
Accrued inventory purchases	474
Accrued interest	440		683
Accrued sales commission	281		1,743
Customer contracts liabilities	108		686
Travel and entertainment	78		280
Other accruals	230		682
Accrued liabilities	4,698	$ 6,996	6,766
Accrued Liabilities [Member]
Current operating lease liabilities	$ 268	$ 230

Note 7 - Note Payable (Details

Note 7 - Note Payable (Details Textual)	Nov. 26, 2019USD ($)$ / shares	Nov. 12, 2019USD ($)$ / sharesshares	Dec. 29, 2017USD ($)	May 22, 2017USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					24,737,618	6,408
Debt Conversion, Converted Instrument, Amount					$ 35,529,000
Notes Payable, Noncurrent, Total					3,983,000	30,528,000
Share Price | $ / shares	$ 0.869
Gains (Losses) on Restructuring of Debt	$ (6,705,000)				$ (6,705,000)
Series B Preferred Stock [Member]
Conversion of Stock, Conversion Rate | $ / shares					$ 1.53
Preferred Stock, Fair Value, Per Share | $ / shares	$ 1,023.23
Convertible Preferred Stock, Fair Value	$ 32,027,000
Series B Preferred Stock [Member] | Measurement Input, Option Volatility [Member]
Convertible Preferred Stock, Measurement Input	73
Series B Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Convertible Preferred Stock, Measurement Input	2
Series B Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Convertible Preferred Stock, Measurement Input	1.58
Minimum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Conversion Rate | $ / shares		$ 1.53
Maximum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Conversion Rate | $ / shares		$ 1.836
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount		$ 28,981,000
Debt Conversion, Converted Instrument, Amount		$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares		31,300
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrants and Rights Outstanding, Term				10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				2,220	2,220	2,220
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 950	$ 950	$ 950
Warrants and Rights Outstanding				$ 940,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Warrants and Rights Outstanding, Term		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		9,893,776			9,893,776
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 1.84
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate		120.00%
Warrants and Rights Outstanding	$ 3,502,000	$ 3,502,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount				20,000,000
Debt Agreement, Covenant, Additional Funding				10,000,000
Debt Agreement, Maximum Borrowing Capacity				$ 30,000,000
Proceeds from Lines of Credit, Total			$ 10,000,000
Debt Instrument, Term				6 years
Debt instrument, Interest Only Payment, Period				4 years
Debt Instrument, Interest Rate, Stated Percentage				12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period				4.00%
Paid-in-Kind Interest					$ 1,226,000	$ 1,256,000
Debt Instrument, Prepayment Fee, Percentage				5.00%
Debt Instrument, Covenant, Cash and Cash Equivalents				$ 2,000,000
Debt Instrument, Back-end Facility Fee Percentage of Principal		25.00%		5.00%
Notes Payable, Noncurrent, Total					$ 3,983,000	$ 30,528,000

Note 7 - Note Payable - Summary

Note 7 - Note Payable - Summary of Note Payable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
2020
2021
2022
2023	5,992,000
Total payments	5,992,000
Less: Amount representing interest	(1,997,000)
Present value of obligations	3,995,000
Less: Unamortized debt discount	(12,000)
Note payable, noncurrent portion	$ 3,983,000	$ 30,528,000

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	1 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Feb. 01, 2017USD ($)ft²
Operating Leases, Rent Expense, Total			$ 358,000
Operating Lease, Cost		$ 301,000
Operating Lease, Weighted Average Remaining Lease Term		1 year 150 days
Operating Lease, Weighted Average Discount Rate, Percent		12.50%
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | ft²				12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year				20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year				21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year				21.75
Security Deposit				$ 22,000
Operating Leases, Allowance for Certain Improvements				$ 88,000
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract	3 years
Operating Leases, Monthly Payment	$ 3,000
Leases of Viveve Systems [Member]
Operating Lease, Property Plant and Equipment, Amount		$ 1,117,000
Lessor, Operating Lease, Depreciation on Leased Assets		$ 121,000

Note 8 - Leases - Lease Assets

Note 8 - Leases - Lease Assets and Liabilities (Details) - USD ($)	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Right-of-Use Asset	$ 395,000	$ 629,000
Accrued Liabilities [Member]
Current operating lease liabilities	268,000	230,000
Other Noncurrent Liabilities [Member]
Noncurrent operating lease liabilities	132,000	399,000
Accrued Liabilities and Other Noncurrent Liabilities [Member]
	$ 400,000	$ 629,000

Note 8 - Leases - Maturity of O

Note 8 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($)	Dec. 31, 2019	Jan. 01, 2019
2020	$ 303,000
2021	137,000
Total lease payments	440,000
Less: Amount representing interest	(40,000)
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Present value of lease liabilities	$ 400,000	$ 629,000

Note 8 - Leases - Minimum Futur

Note 8 - Leases - Minimum Future Rentals (Details) $ in Thousands	Dec. 31, 2019USD ($)
2020	$ 662
Thereafter
Total	$ 662

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - USD ($)	Nov. 26, 2019	Dec. 31, 2019	Nov. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Series A Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted		3,021,237	600,000
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion		1	1	1
Preferred Stock, Shares Outstanding, Ending Balance		1,852,173		1,852,173	0
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance		31,678		31,678	0
Preferred Stock, Dividend Rate, Percentage	12.50%
Preferred Stock Dividends, Shares				378
Dividends, Preferred Stock, Cash				$ 2,400
Preferred Stock, Fair Value, Per Share	$ 1,023.23
Convertible Preferred Stock, Fair Value	$ 32,027,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	31,300

Note 11 - Common Stock (Details

Note 11 - Common Stock (Details Textual)	Aug. 16, 2019USD ($)	Feb. 12, 2018USD ($)	Nov. 08, 2017USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Nov. 30, 2019USD ($)$ / sharesshares	Oct. 31, 2019USD ($)	Aug. 31, 2019USD ($)shares	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Feb. 28, 2018USD ($)shares	Nov. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Nov. 26, 2019USD ($)	Nov. 12, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	May 22, 2017USD ($)yr$ / sharesshares
Shares Issued, Price Per Share | $ / shares										$ 2.56
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				24,737,618					6,408				24,737,618	6,408
Stock Issued During Period, Value, Restricted Stock Award, Gross | $										$ 256,000			$ 74,000	$ 336,000
Proceeds from Issuance of Common Stock | $													16,274,000	53,792,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross										1,000
Amortization of Debt Discount (Premium) | $													352,000	$ 325,000
Debt Instrument, Unamortized Discount, Total | $				$ 12,000									$ 12,000
Class of Warrants or Rights, Exercises in Period													0	0
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period													0	0
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period													1,272	0
Share-based Payment Arrangement, Expense | $													$ 2,400,000	$ 3,035,000
The 2017 Loan Agreement [Member]
Debt Issuance Costs, Net, Total | $																	$ 790,000
Restricted Stock [Member]
Proceeds From Issuance of Common Stock, Net | $				30,675		$ 7,740		$ 274
Stock Issued During Period, Value, Restricted Stock Award, Gross | $				$ 25,000		$ 25,000		$ 25,000
Series A Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted				3,021,237	600,000
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate | $ / shares																$ 1.53
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate | $ / shares																$ 1.836
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion				1	1							1	1
Series B Preferred Stock [Member]
Conversion of Stock, Conversion Rate | $ / shares				$ 1.53									$ 1.53
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.55	$ 1.55							$ 1.55	$ 1.55
Warrants and Rights Outstanding, Term					1 year							1 year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				7,419,353	7,419,353							7,419,353	7,419,353
Warrants and Rights Outstanding | $					$ 1,210,000							$ 1,210,000
Series A Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0							0
Series A Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input					91.1							91.1
Series A Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input					1.59							1.59
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.55	$ 1.55							$ 1.55	$ 1.55
Warrants and Rights Outstanding, Term					5 years							5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				7,419,353	7,419,353							7,419,353	7,419,353
Warrants and Rights Outstanding | $					$ 2,871,000							$ 2,871,000
Series B Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0							0
Series B Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input					68.8							68.8
Series B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input					1.58							1.58
Series A and Series B Warrants [Member]
Warrants and Rights Outstanding | $					$ 4,081,000							$ 4,081,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.84									$ 1.84
Warrants and Rights Outstanding, Term																5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				9,893,776									9,893,776			9,893,776
Warrants and Rights Outstanding | $															$ 3,502,000	$ 3,502,000
Class of Warrants or Rights, Outstanding, Percentage of Common Stock																15.00%
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate																120.00%
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																0
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																68.8
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																1.58
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 950					$ 950				$ 950	$ 950				$ 950
Warrants and Rights Outstanding, Term																		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				2,220					2,220				2,220	2,220				2,220
Warrants and Rights Outstanding | $																		$ 940,000
Share-based Payment Arrangement, Expense | $													$ 0	$ 0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																		0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																		0.551
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																		0.0225
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr																		10
Class A Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 1.55							$ 1.55
Warrants and Rights Outstanding, Term					1 year							1 year
Class A Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 1.55							$ 1.55
Warrants and Rights Outstanding, Term					5 years							5 years
Class B Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 1.55							$ 1.55
Warrants and Rights Outstanding, Term					1 year							1 year
Class B Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 1.55							$ 1.55
Warrants and Rights Outstanding, Term					5 years							5 years
Common Stock [Member]
Stock Issued During Period, Value, Restricted Stock Award, Gross | $
Stock Issued During Period, Shares, Restricted Stock Award, Gross													1,169	1,285
November 2019 Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $					$ 11,500,000
Proceeds From Issuance of Common Stock, Net | $					$ 9,952,000
November 2019 Offering [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues					5,473,410
November 2019 Offering [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues												5,473,410
November 2019 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share | $ / shares					$ 1.55							$ 1.55
Common Shares Per Unit					1							1
November 2019 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share | $ / shares					$ 1.55							$ 1.55
Series A Convertible Preferred Stock Per Unit					1							1
November 2019 Offering [Member] | Class B Units [Member] | Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion					1							1
November 2019 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues					1,945,943							1,945,943	1,945,943
August 2019 ATM Facility [Member]
Proceeds From Issuance of Common Stock, Net | $													$ 6,322,000
Stock Issued During Period, Shares, New Issues													1,004,171
Aggregate Offering Price | $	$ 6,760,000						$ 6,760,000
August 2019 ATM Facility [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues													1,004,171
November 2017 ATM Facility [Member]
Proceeds From Issuance of Common Stock, Net | $					$ 1,193,000		$ 1,318,000							$ 1,193,000
Stock Issued During Period, Shares, New Issues					2,771		3,364						0	2,771
Aggregate Offering Price | $			$ 25,000,000				$ 25,000,000
November 2017 ATM Facility [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues														2,771
December 2018 Offering [Member]
Proceeds From Issuance of Common Stock, Net | $									$ 20,384,000
Stock Issued During Period, Shares, New Issues									147,285
Proceeds from Issuance of Common Stock | $									$ 22,093,000
December 2018 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues														147,285
February 2018 Offering [Member]
Proceeds From Issuance of Common Stock, Net | $		$ 32,214,000									$ 32,214,000
Stock Issued During Period, Shares, New Issues											115,000
Stock Issued During Period, Value, Restricted Stock Award, Gross | $		115,000
Proceeds from Issuance of Common Stock | $		$ 34,500,000									$ 34,500,000
February 2018 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues														115,000

Note 11 - Common Stock - Summar

Note 11 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Nov. 30, 2019	Nov. 12, 2019	May 22, 2017
Shares Outstanding Under Warrants (in shares)	24,737,618	6,408
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 400	$ 400
Shares Outstanding Under Warrants (in shares)	754	754
September 2014 Issuance Through Private Offering [Member]
Expiration Date		Sep. 23, 2019
Exercise Price (in dollars per share)		$ 424
Shares Outstanding Under Warrants (in shares)		859
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 272	$ 272
Shares Outstanding Under Warrants (in shares)	14	14
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date		Oct. 13, 2019
Exercise Price (in dollars per share)		$ 424
Shares Outstanding Under Warrants (in shares)		288
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025	May 12, 2025
Exercise Price (in dollars per share)	$ 424	$ 424
Shares Outstanding Under Warrants (in shares)	362	362
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date		Nov. 12, 2019
Exercise Price (in dollars per share)		$ 424
Shares Outstanding Under Warrants (in shares)		125
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020	May 17, 2020
Exercise Price (in dollars per share)	$ 424	$ 424
Shares Outstanding Under Warrants (in shares)	215	215
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 560	$ 560
Shares Outstanding Under Warrants (in shares)	267	267
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 608	$ 608
Shares Outstanding Under Warrants (in shares)	250	250
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021	May 11, 2021
Exercise Price (in dollars per share)	$ 774	$ 774
Shares Outstanding Under Warrants (in shares)	50	50
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 498	$ 498
Shares Outstanding Under Warrants (in shares)	1,004	1,004
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027	May 25, 2027
Exercise Price (in dollars per share)	$ 950	$ 950			$ 950
Shares Outstanding Under Warrants (in shares)	2,220	2,220			2,220
Series A Warrants [Member]
Expiration Date	Nov. 26, 2020
Exercise Price (in dollars per share)	$ 1.55		$ 1.55
Shares Outstanding Under Warrants (in shares)	7,419,353		7,419,353
Series B Warrants [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share)	$ 1.55		$ 1.55
Shares Outstanding Under Warrants (in shares)	7,419,353		7,419,353
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share)	$ 1.84
Shares Outstanding Under Warrants (in shares)	9,893,776			9,893,776

Note 12 - Summary of Stock Op_3

Note 12 - Summary of Stock Options (Details Textual) - USD ($)	Dec. 31, 2019	Sep. 30, 2019	Jun. 28, 2019	Mar. 29, 2019	Dec. 31, 2018	Sep. 28, 2018	Jun. 29, 2018	May 30, 2018	Mar. 29, 2018	Aug. 31, 2017	Aug. 22, 2016	Sep. 30, 2019	Jul. 31, 2019	Jun. 30, 2019	Apr. 30, 2019	Jan. 31, 2019	Dec. 31, 2018	Oct. 30, 2018	Jul. 31, 2018	Jun. 30, 2018	Apr. 30, 2018	Jan. 31, 2018	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Nov. 26, 2019	Jan. 01, 2019	Jan. 01, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	10,087,678				40,144												40,144						10,087,678	10,087,678	40,144	26,903
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 2.22				$ 455.68												$ 455.68						$ 2.22	$ 2.22	$ 455.68	$ 579.81
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																								9 years 328 days	7 years 146 days	8 years 219 days
Stock Issued During Period, Shares, Restricted Stock Award, Gross																				1,000
Shares Issued, Price Per Share																				$ 2.56
Proceeds from Stock Plans																								$ 56,000	$ 233,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																								10,065,844	23,542
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																								0.00%	0.00%
Director [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross													378		525
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period															525
Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross														250
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																								0.00%	0.00%
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Accelerated Cost								$ 97,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																								0.00%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 7,640,000																						$ 7,640,000	$ 7,640,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition																								3 years 109 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	2,640																						2,640	2,640
Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value													$ 38.08		$ 91
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	104																						104	104
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0																						0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 992																						$ 992	$ 992
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																								3 years 36 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	10,087,574																						10,087,574	10,087,574
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,798,337																						1,798,337	1,798,337
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 2.21																						$ 2.21	$ 2.21
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																								9 years 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																								4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum																								10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent																								110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock											4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	11,872,531				49,140												49,140						11,872,531	11,872,531	49,140	40,000	11,872,531	69,571	49,140
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized																20,431
Common Stock Shares Reserved For Future Issuance Percentage		18.00%										18.00%
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																								9,528,869	21,419
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value																								$ 0.73	$ 224.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																								0	0
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																								536,975	2,123
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value																								$ 0.61	$ 162.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																								0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																3,625
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period																								1,255
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																								0
The 2013 Plan [Member] | Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value													$ 38.08		$ 91		$ 105	$ 248	$ 263		$ 344	$ 519
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period													378		525		407	178	181		144	943
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period													378		525		407	178	182		144	94
The 2013 Plan [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																				2 years		1 year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value																				$ 358		$ 497
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																				500		250
The 2013 Plan [Member] | Restricted Stock [Member] | Consultant [Member] | June 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																							250
The 2013 Plan [Member] | Restricted Stock [Member] | Consultant [Member] | January 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																									250
The 2013 Plan [Member] | Underwritten Public Offering [Member]
Minimum Gross Proceeds From Equity Offering Amount Used In Calculation Of Reserved Shares Percentage												$ 5,000,000
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																								5 years
2017 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee										200
Stock Issued During Period, Shares, Employee Stock Purchase Plans	300	200	602	429	494	274	243		198															1,531	1,209
Shares Issued, Price Per Share	$ 1.07	$ 3.75	$ 32.30	$ 79.88	$ 89.25	$ 223.55	$ 231.20		$ 311.10			$ 3.75					$ 89.25						$ 1.07	$ 1.07	$ 89.25
Proceeds from Stock Plans																								$ 233,000	$ 56,000
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares	1,092																						1,092	1,092
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased																								$ 22.75	$ 89
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																								0.00%	0.00%

Note 12 - Summary of Stock Op_4

Note 12 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Options outstanding (in shares)	40,144	26,903
Options outstanding, weighted average exercise price (in dollars per share)	$ 455.68	$ 579.81
Options outstanding, weighted average remaining contractual term (Year)	9 years 328 days	7 years 146 days	8 years 219 days
Options outstanding, aggregate intrinsic value	$ 3,928,715		$ 249,154
Options granted (in shares)	10,065,844	23,542
Options granted, weighted average exercise price (in dollars per share)	$ 1.14	$ 351.81
Options exercised (in shares)
Options exercised, weighted average exercise price (in dollars per share)
Options canceled (in shares)	(18,310)	(10,301)
Options canceled, weighted average exercise price (in dollars per share)	$ 403.31	$ 548.13
Options outstanding (in shares)	10,087,678	40,144	26,903
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.22	$ 455.68	$ 579.81
Vested and exercisable and expected to vest, end of period (in shares)	8,966,825
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share)	$ 2.36
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year)	9 years 328 days
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value	$ 3,490,722
Vested and exercisable, end of period (in shares)	222,582
Vested and exercisable, end of period, weighted average exercise price (in dollars per share)	$ 41.49
Vested and exercisable, end of period, weighted average remaining contractual term (Year)	9 years 182 days
Vested and exercisable, end of period, aggregate intrinsic value	$ 77,540

Note 12 - Summary of Stock Op_5

Note 12 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Options outstanding, number (in shares) | shares	10,087,678
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.22
Options outstanding, weighted average remaining contractual term (Year)	9 years 328 days
Options exercisable, number exercisable (in shares) | shares	222,582
Options exercisable, weighted average exercise price (in dollars per share)	$ 41.49
Range One [Member]
Exercise price range, lower limit (in dollars per share)	0.86
Exercise price range, upper limit (in dollars per share)	$ 0.89
Options outstanding, number (in shares) | shares	10,042,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.87
Options outstanding, weighted average remaining contractual term (Year)	9 years 328 days
Options exercisable, number exercisable (in shares) | shares	198,312
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.87
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	38
Exercise price range, upper limit (in dollars per share)	$ 58
Options outstanding, number (in shares) | shares	1,650
Options outstanding, weighted average exercise price (in dollars per share)	$ 55.42
Options outstanding, weighted average remaining contractual term (Year)	9 years 146 days
Options exercisable, number exercisable (in shares) | shares
Options exercisable, weighted average exercise price (in dollars per share)
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	100
Exercise price range, upper limit (in dollars per share)	$ 197
Options outstanding, number (in shares) | shares	22,385
Options outstanding, weighted average exercise price (in dollars per share)	$ 140.23
Options outstanding, weighted average remaining contractual term (Year)	8 years 36 days
Options exercisable, number exercisable (in shares) | shares	9,141
Options exercisable, weighted average exercise price (in dollars per share)	$ 144.93
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	202
Exercise price range, upper limit (in dollars per share)	$ 283
Options outstanding, number (in shares) | shares	775
Options outstanding, weighted average exercise price (in dollars per share)	$ 252.06
Options outstanding, weighted average remaining contractual term (Year)	8 years
Options exercisable, number exercisable (in shares) | shares	355
Options exercisable, weighted average exercise price (in dollars per share)	$ 255.75
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	311
Exercise price range, upper limit (in dollars per share)	$ 382
Options outstanding, number (in shares) | shares	3,833
Options outstanding, weighted average exercise price (in dollars per share)	$ 355.39
Options outstanding, weighted average remaining contractual term (Year)	6 years
Options exercisable, number exercisable (in shares) | shares	2,423
Options exercisable, weighted average exercise price (in dollars per share)	$ 362.12
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	430
Exercise price range, upper limit (in dollars per share)	$ 497
Options outstanding, number (in shares) | shares	7,870
Options outstanding, weighted average exercise price (in dollars per share)	$ 453.47
Options outstanding, weighted average remaining contractual term (Year)	6 years 146 days
Options exercisable, number exercisable (in shares) | shares	5,066
Options exercisable, weighted average exercise price (in dollars per share)	$ 454.44
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	501
Exercise price range, upper limit (in dollars per share)	$ 567
Options outstanding, number (in shares) | shares	4,215
Options outstanding, weighted average exercise price (in dollars per share)	$ 536.47
Options outstanding, weighted average remaining contractual term (Year)	5 years 255 days
Options exercisable, number exercisable (in shares) | shares	3,258
Options exercisable, weighted average exercise price (in dollars per share)	$ 535.73
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	600
Exercise price range, upper limit (in dollars per share)	$ 661
Options outstanding, number (in shares) | shares	2,372
Options outstanding, weighted average exercise price (in dollars per share)	$ 601.29
Options outstanding, weighted average remaining contractual term (Year)	3 years 219 days
Options exercisable, number exercisable (in shares) | shares	2,352
Options exercisable, weighted average exercise price (in dollars per share)	$ 600.78
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	700
Exercise price range, upper limit (in dollars per share)	$ 792
Options outstanding, number (in shares) | shares	1,974
Options outstanding, weighted average exercise price (in dollars per share)	$ 768.12
Options outstanding, weighted average remaining contractual term (Year)	6 years 255 days
Options exercisable, number exercisable (in shares) | shares	1,571
Options exercisable, weighted average exercise price (in dollars per share)	$ 768.19
Range Ten [Member]
Exercise price range, lower limit (in dollars per share)	992
Exercise price range, upper limit (in dollars per share)	$ 992
Options outstanding, number (in shares) | shares	104
Options outstanding, weighted average exercise price (in dollars per share)	$ 992
Options outstanding, weighted average remaining contractual term (Year)	3 years 36 days
Options exercisable, number exercisable (in shares) | shares	104
Options exercisable, weighted average exercise price (in dollars per share)	$ 992

Note 12 - Summary of Stock Op_6

Note 12 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Expected term (Year)	6 years	5 years
Average volatility	70.00%	73.00%
Risk-free interest rate	1.62%	2.65%
Dividend yield	0.00%	0.00%
2017 Employee Stock Purchase Plan [Member]
Expected term (Year)	91 days	91 days
Average volatility	87.00%	72.00%
Risk-free interest rate	2.29%	1.92%
Dividend yield	0.00%	0.00%

Note 12 - Summary of Stock Op_7

Note 12 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Expected term (Year)	6 years	5 years
Average volatility	70.00%	73.00%
Risk-free interest rate	1.62%	2.65%
Dividend yield	0.00%	0.00%
Nonemployees [Member]
Expected term (Year)	6 years	9 years
Average volatility	70.00%	69.00%
Risk-free interest rate	1.69%	2.69%
Dividend yield	0.00%	0.00%

Note 12 - Summary of Stock Op_8

Note 12 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock-based compensation expense	$ 2,400	$ 3,035
Cost of Sales [Member]
Stock-based compensation expense	135	69
Research and Development Expense [Member]
Stock-based compensation expense	192	328
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 2,073	$ 2,638

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Expense (Benefit), Total	$ 0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(16,506,000)	$ 11,667,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	527,000	951,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0
Unrecognized Tax Benefits, Ending Balance	223,000	$ 450,000	$ 397,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	77,333,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	6,171,000
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 742,000

Note 13 - Income Taxes - Provis

Note 13 - Income Taxes - Provision for Income Taxes Computed at Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income tax provision (benefit) at statutory rate	(21.00%)	(21.00%)
State income taxes, net of federal benefit	(4.00%)	(4.00%)
Change in valuation allowance	(39.00%)	23.00%
Debt restructuring	6.00%	0.00%
Limitation on net operating loss and credit carryovers	56.00%	0.00%
Other	2.00%	2.00%
Effective tax rate	0.00%	0.00%

Note 13 - Income Taxes - Signif

Note 13 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Net operating loss carryforwards	$ 16,688	$ 31,759
Capitalized start up costs	3,225	3,555
Research and development credits	527	951
Accruals and reserves	532	1,272
Fixed assets and depreciation	(128)	(69)
Total deferred tax assets	21,100	37,606
Valuation allowance	(21,100)	(37,606)
Net deferred tax assets

Note 13 - Income Taxes - Unreco

Note 13 - Income Taxes - Unrecognized Tax Benefit Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Balance	$ 450,000	$ 397,000
Additions (deletions) based upon tax positions related to the current year	(227,000)	53,000
Balance	$ 223,000	$ 450,000

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	12 Months Ended		123 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Stock Issued During Period, Shares, New Issues			375
Related Party Transaction, Amounts of Transaction	$ 4,889,000	$ 10,150,000

Note 15 - Segments and Geogra_3

Note 15 - Segments and Geographic Information (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Long-lived assets	$ 3,046	$ 2,916
UNITED STATES
Long-lived assets	2,818	2,851
Asia Pacific [Member]
Long-lived assets	64	24
CANADA
Long-lived assets	142	28
Latin America [Member]
Long-lived assets		5
Europe [Member]
Long-lived assets	$ 22	$ 8

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)

Jan. 01, 2020

Feb. 28, 2020

Jan. 31, 2020

Dec. 31, 2019

Nov. 30, 2019

Jan. 31, 2019

Feb. 19, 2020

Nov. 26, 2019

Jan. 01, 2019

Dec. 31, 2018

Jan. 01, 2018

Dec. 31, 2017

Series A Preferred Stock [Member]

Preferred Stock, Shares Outstanding, Ending Balance

1,852,173

0

Series A Convertible Preferred Stock Into Common Stock [Member]

Conversion of Stock, Shares Converted

3,021,237

600,000

Subsequent Event [Member] | Series A Warrants [Member]

Stock Issued During Period, Shares, Warrant Exercises

1,026,240

Proceeds from Warrant Exercises

$ 1,591,000

Subsequent Event [Member] | Series B Warrants [Member]

Stock Issued During Period, Shares, Warrant Exercises

45,473

Proceeds from Warrant Exercises

$ 70,000

Subsequent Event [Member] | Series A Preferred Stock [Member]

Preferred Stock, Shares Outstanding, Ending Balance

0

Subsequent Event [Member] | Series A Convertible Preferred Stock Into Common Stock [Member]

Conversion of Stock, Shares Converted

669,022

1,183,151

The 2013 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

20,431

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

11,872,531

11,872,531

69,571

49,140

49,140

40,000

The 2013 Plan [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

2,639,926

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

14,512,457